'''(-)-1-(Benzofuran-2-yl)-2-propylaminopentane''' ('''(-)-BPAP'''),<ref>US Patent 6214859</ref> BFPAPn, or BFPAP is a [[drug]] with an unusual effects profile. It can loosely be grouped with the [[stimulant]] or [[antidepressant]] drug families, but its mechanism of action is quite different.<ref>Shimazu S, Takahata K, Katsuki H, Tsunekawa H, Tanigawa A, Yoneda F, Knoll J, Akaike A. (-)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release. ''European Journal of Pharmacology''. 2001; 421: 181-189.</ref><ref>Shimazu S, Tsunekawa H, Yoneda F, Katsuki H, Akaike A, Janowsky A. Transporter Mediated Actions of R-(-)-1-(Benzofuran-2-yl)-2-propylaminopentane. ''European Journal of Pharmacology''. 2003; 482: 9-16.</ref>

 
BPAP has been shown to have [[neuroprotective]] effects similar to those of selegiline, and has been researched for the treatment of [[Alzheimer's disease]], [[Parkinson's disease]] and [[clinical depression]].<ref>Gaszner P, Miklya I. Major depression and the synthetic enhancer substances (-)-deprenyl and (-)-1-(Benzofuran-2-yl)-2-propylaminopentane. ''Progress in Neuropsychopharmacology & Biological Psychiatry''. 2006 Jan;30(1):5-14.</ref>
